Innovent opens dosing in Phase 1 trial of TED antibody IBI3031
The China-based safety study enrolls patients with active thyroid eye disease as Innovent adds an eighth mechanism to a field already anchored by teprotumumab and three late-stage rivals.
Executive Summary
- Innovent Biologics started dosing patients in a first-in-human safety study of its thyroid eye disease antibody, moving the trial from planning into active recruitment on schedule.
- The trial is built entirely around safety, tolerability, and pharmacokinetics, with efficacy measures such as proptosis and diplopia response tracked only as secondary and exploratory readouts.
- Thyroid eye disease already has an approved IGF-1R antibody and a field of late-stage entrants targeting IGF-1R and FcRn, so Innovent's asset joins a mechanism-diverse field without a disclosed target of its own to differentiate it.
- The status change and steady enrollment target signal ordinary trial execution, shifting the open question from whether the study will start to what its tolerability data will show heading into next year.
The trial
NCT07622368 tests IBI3031A101, a monoclonal antibody, in adults in China with moderate-to-severe active thyroid eye disease who test positive for thyrotrophin receptor antibody. The study targets 66 participants across single- and multiple-ascending-dose cohorts, with a primary completion date of June 15, 2027. Its 14 primary endpoints cover vital signs, laboratory chemistry, hearing thresholds, ECG changes, and adverse-event rates rather than disease activity, marking this as a safety and tolerability study, not an efficacy readout. NCT07622368A Study of IBI3031 in Participants With Thyroid Eye DiseaseNCT07622368
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What it can establish
A single-ascending and multiple-ascending dose design in 66 participants is built to characterize tolerability and pharmacokinetics, including area under the curve, clearance, and half-life, across dose levels. Secondary measures track Clinical Activity Score change, proptosis response, and diplopia response, giving an early signal on biological activity even though the trial is not powered or designed to establish efficacy. That structure means the trial's most decision-relevant output is whether adverse events, including serious adverse events, cluster at higher doses. NCT07622368A Study of IBI3031 in Participants With Thyroid Eye DiseaseNCT07622368
The competitive field
Thyroid eye disease already has an approved IGF-1R-targeting antibody, teprotumumab, and the field includes multiple Phase 3 programs targeting IGF-1R and FcRn alongside earlier-stage entrants, according to competitive-trial data drawn across the indication. IBI3031A101's own target is not established in available records, so it cannot yet be placed on this target map, but the field itself spans at least two validated mechanisms and remains active with new entrants at Phase 1 and Phase 2.
Execution context
The enrollment target held flat at 66 participants with no increase or reduction, a pattern the operational risk model treats as routine for a Phase 1 study. No amendments changed the primary completion date, and the only registry event since the trial's June 3, 2026 posting was the status change to Recruiting itself. Innovent's broader pipeline shows an 87% completion rate across 115 trials, with 15 terminated among 185 total studies tracked, providing a base rate for sponsor execution without pointing to any specific concern in this program. NCT07622368A Study of IBI3031 in Participants With Thyroid Eye DiseaseNCT07622368
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.